Receive our newsletter – data, insights and analysis delivered to you
July 16, 2009

QI Begins Breast Cancer Immunotherapy Trials

Quantum Immunologics (QI) has begun a US Food and Drug Association-authorised trial to test the safety and efficacy of the company's new dendritic cell therapy immunotherapy treatment. The trial will be conducted on 27 stage IV breast cancer patients who have failed conventional therapy.

By cms admin

Quantum Immunologics (QI) has begun a US Food and Drug Association-authorised trial to test the safety and efficacy of the company’s new dendritic cell therapy immunotherapy treatment.

The trial will be conducted on 27 stage IV breast cancer patients who have failed conventional therapy.

Mentor Capital, which recently acquired 20% in QI, CEO Chet Billingsley said that the company will reveal buying opportunities soon now that the company has reached the clinical stage.

Dendritic cell therapy employs oncofoetal antigen (OFA) to recruit the patient’s own immune system to target and attack the cancer cells.

Each patient will receive three monthly injections of their own dendritic cells that have been sensitised to OFA.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU